Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Cash & Equivalents (2016 - 2026)

Collegium Pharmaceutical has reported Cash & Equivalents over the past 11 years, most recently at $231.3 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 227.71% year-over-year to $231.3 million; the TTM value through Dec 2025 reached $231.3 million, up 227.71%, while the annual FY2025 figure was $231.3 million, 227.71% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $231.3 million at Collegium Pharmaceutical, up from $150.1 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $283.7 million in Q2 2023 and troughed at $39.0 million in Q3 2024.
  • A 5-year average of $173.0 million and a median of $178.2 million in 2021 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: crashed 84.93% in 2024 and later surged 285.26% in 2025.
  • Year by year, Cash & Equivalents stood at $186.4 million in 2021, then decreased by 6.83% to $173.7 million in 2022, then skyrocketed by 37.57% to $238.9 million in 2023, then tumbled by 70.47% to $70.6 million in 2024, then skyrocketed by 227.71% to $231.3 million in 2025.
  • Business Quant data shows Cash & Equivalents for COLL at $231.3 million in Q4 2025, $150.1 million in Q3 2025, and $117.3 million in Q2 2025.